Last reviewed 2026-04-23 · How we verify

Drug: LYC-30937-EC

Lycera Corp. · Phase 2 active Small molecule

Drug: LYC-30937-EC is a Immunomodulator Small molecule drug developed by Lycera Corp.. It is currently in Phase 2 development for Treatment of autoimmune diseases.

LYC-30937-EC is an immunomodulatory drug.

LYC-30937-EC is an immunomodulatory drug. Used for Treatment of autoimmune diseases.

At a glance

Generic name	Drug: LYC-30937-EC
Sponsor	Lycera Corp.
Drug class	Immunomodulator
Target	Unknown
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

It modulates the immune system by targeting specific immune cells, potentially leading to therapeutic effects in various diseases.

Approved indications

Treatment of autoimmune diseases

Common side effects

Unknown

Key clinical trials

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Drug: LYC-30937-EC CI brief — competitive landscape report
Drug: LYC-30937-EC updates RSS · CI watch RSS
Lycera Corp. portfolio CI

Frequently asked questions about Drug: LYC-30937-EC

What is Drug: LYC-30937-EC?

Drug: LYC-30937-EC is a Immunomodulator drug developed by Lycera Corp., indicated for Treatment of autoimmune diseases.

How does Drug: LYC-30937-EC work?

LYC-30937-EC is an immunomodulatory drug.

What is Drug: LYC-30937-EC used for?

Drug: LYC-30937-EC is indicated for Treatment of autoimmune diseases.

Who makes Drug: LYC-30937-EC?

Drug: LYC-30937-EC is developed by Lycera Corp. (see full Lycera Corp. pipeline at /company/lycera-corp).

What drug class is Drug: LYC-30937-EC in?

Drug: LYC-30937-EC belongs to the Immunomodulator class. See all Immunomodulator drugs at /class/immunomodulator.

What development phase is Drug: LYC-30937-EC in?

Drug: LYC-30937-EC is in Phase 2.

What are the side effects of Drug: LYC-30937-EC?

Common side effects of Drug: LYC-30937-EC include Unknown.

What does Drug: LYC-30937-EC target?

Drug: LYC-30937-EC targets Unknown and is a Immunomodulator.

Drug class: All Immunomodulator drugs
Target: All drugs targeting Unknown
Manufacturer: Lycera Corp. — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Treatment of autoimmune diseases
Compare: Drug: LYC-30937-EC vs similar drugs
Pricing: Drug: LYC-30937-EC cost, discount & access